Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
Johnson & Johnson Pharmaceutical Research & Development, L.L.C. |
---|---|
Information provided by: | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. |
ClinicalTrials.gov Identifier: | NCT00103506 |
This is a randomized, parallel-group, open-label, multicenter study in 18 countries.
Approximately 630 subjects with multiple myeloma whose disease has progressed after an initial response to at least 1 line of prior therapy or was refractory to initial treatment will be enrolled.
Condition | Intervention | Phase |
---|---|---|
Multiple Myeloma |
Drug: DOXIL/CAELYX |
Phase III |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Open Label, Active Control, Parallel Assignment, Safety/Efficacy Study |
Official Title: | A Randomized Controlled Study of DOXIL/CAELYX (Doxorubicin HCL Liposome Injection) and VELCADE (Bortezomib) or VELCADE Monotherapy for the Treatment of Relapsed Multiple Myeloma |
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Study Director: | Johnson & Johnson Pharmaceutical Research & Development, L.L.C | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. |
Study ID Numbers: | DOXIL MMY 3001 |
Study First Received: | February 9, 2005 |
Last Updated: | April 12, 2007 |
ClinicalTrials.gov Identifier: | NCT00103506 |
Health Authority: | United States: Food and Drug Administration |
multiple myeloma Relapse Multiple myeloma |
Immunoproliferative Disorders Blood Protein Disorders Hematologic Diseases Blood Coagulation Disorders Bortezomib Vascular Diseases Paraproteinemias |
Hemostatic Disorders Doxorubicin Multiple Myeloma Hemorrhagic Disorders Multiple myeloma Lymphoproliferative Disorders Neoplasms, Plasma Cell |
Neoplasms Neoplasms by Histologic Type Molecular Mechanisms of Pharmacological Action Immune System Diseases Antineoplastic Agents Therapeutic Uses |
Enzyme Inhibitors Cardiovascular Diseases Antibiotics, Antineoplastic Pharmacologic Actions Protease Inhibitors |